Tufts University scientists are aiming to revolutionize the future of weight loss drugs by engineering a new compound that ...

GLP-1 medications offer promising benefits for obesity and diabetes patients, with studies showing reduced heart attack risk ...

Patients on GLP-1 medications lost about half as much weight as participants did in clinical trials, NYU researchers found.

Pennsylvania Governor Josh Shapiro's office has said it is looking to change eligibility for weight loss drugs as part of its 2025-26 budget plans.

At last week’s Flow Space Women’s Health Forum, triple board-certified endocrinologist Dr. Rocio Salas-Whalen sat before a ...

Now, a study ... in U.S. adults with diabetes who took these popular medications compared to those who took another class of diabetes drug not associated with weight loss. This type of study ...

Weight-loss drugs like Ozempic and Wegovy are used by more than 15 million adults in the U.S., or 4.5% of the population.

GLP-1 drugs like Ozempic and Wegovy have been linked to a host of benefits beyond diabetes management and weight loss, from reduced dementia risk to addiction treatment. Now new research out of ...

Weight-loss medications known as glucagon-like peptide-1 (GLP-1) agonists, which have gained popularity for treating type 2 diabetes and ... third of them were not available for follow-up.